Skip to content

Research at St Andrews

The potential for treatment shortening with higher rifampicin doses: relating drug exposure to treatment response in patients with pulmonary tuberculosis

Research output: Contribution to journalArticle

DOI

Open Access permissions

Open

Author(s)

Elin M Svensson, Robin J Svensson, Lindsey H M Te Brake, Martin J Boeree, Norbert Heinrich, Sarah Konsten, Gavin Churchyard, Rodney Dawson, Andreas H Diacon, Gibson S Kibiki, Lilian T Minja, Nyanda E Ntingiya, Ian Sanne, Stephen H Gillespie, Michael Hoelscher, Patrick P J Phillips, Ulrika S H Simonsson, Rob Aarnoutse

School/Research organisations

Abstract

Background: Tuberculosis remains a huge public health problem and the prolonged treatment duration obstructs effective tuberculosis control. Higher rifampicin doses have been associated with better bactericidal activity, but optimal dosing is uncertain. This analysis aimed to characterize the relationship between rifampicin plasma exposure and treatment response over 6 months in a recent study investigating the potential for treatment shortening with high-dose rifampicin.

Methods: Data were analyzed from 336 patients with pulmonary tuberculosis (97 with pharmacokinetic data) treated with rifampicin doses of 10, 20, or 35 mg/kg. The response measure was time to stable sputum culture conversion (TSCC). We derived individual exposure metrics with a previously developed population pharmacokinetic model of rifampicin. TSCC was modeled using a parametric time-to-event approach, and a sequential exposure-response analysis was performed.

Results: Higher rifampicin exposures increased the probability of early culture conversion. No maximal limit of the effect was detected within the observed range. The expected proportion of patients with stable culture conversion on liquid medium at week 8 was predicted to increase from 39% (95% confidence interval, 37%-41%) to 55% (49%-61%), with the rifampicin area under the curve increasing from 20 to 175 mg/L·h (representative for 10 and 35 mg/kg, respectively). Other predictors of TSCC were baseline bacterial load, proportion of culture results unavailable, and substitution of ethambutol for either moxifloxacin or SQ109.

Conclusions: Increasing rifampicin exposure shortened TSCC, and the effect did not plateau, indicating that doses >35 mg/kg could be yet more effective. Optimizing rifampicin dosage while preventing toxicity is a clinical priority.

Close

Details

Original languageEnglish
Pages (from-to)34-41
Number of pages8
JournalClinical Infectious Diseases
Volume67
Issue number1
Early online date21 Mar 2018
DOIs
Publication statusPublished - 18 Jun 2018

    Research areas

  • High-dose rifampicin, Pharmacometrics, PK-PD, Exposure-response, Sputum culture conversion

Discover related content
Find related publications, people, projects and more using interactive charts.

View graph of relations

Related by author

  1. Mimicking in-vivo exposures to drug combinations in-vitro: anti-tuberculosis drugs in lung lesions and the hollow fiber model of infection

    Kloprogge, F., Hammond, R., Kipper, K., Gillespie, S. H. & Della Pasqua, O., 13 Sep 2019, In : Scientific Reports. 9, 8 p., 13228.

    Research output: Contribution to journalArticle

  2. A tuberculosis molecular bacterial load assay (TB-MBLA)

    Sabiiti, W., Mtafya, B. A., Alferes De Lima, D., Dombay, E., Baron, V. O., Azam, K., Orascova, K., Sloan, D. J. & Gillespie, S. H., 6 Sep 2019, (Accepted/In press) In : Journal of Visualized Experiments.

    Research output: Contribution to journalArticle

  3. Can phenotypic data complement our understanding of antimycobacterial effects for drug combinations?

    Kloprogge, F., Hammond, R., Copas, A., Gillespie, S. H. & Della Pasqua, O., 25 Aug 2019, In : Journal of Antimicrobial Chemotherapy. Advance article, 7 p.

    Research output: Contribution to journalArticle

  4. Toxicity related to standard TB therapy for pulmonary tuberculosis and treatment outcomes in the REMoxTB study according to HIV status

    Tweed, C. D., Crook, A. M., Dawson, R., Diacon, A. H., McHugh, T. D., Mendel, C. M., Meredith, S. K., Mohapi, L., Murphy, M. E., Nunn, A. J., Phillips, P. P. J., Singh, K. P., Spigelman, M. & Gillespie, S. H., 14 Aug 2019, In : BMC Pulmonary Medicine. 19, 9 p., 152.

    Research output: Contribution to journalArticle

  5. Model-based relationship between the molecular bacterial load assay and time-to-positivity in liquid culture

    Svensson, R. J., Sabiiti, W., Kibiki, G. S., Ntinginya, N. E., Bhatt, N., Davies, G., Gillespie, S. H. & Simonsson, U. S. H., 29 Jul 2019, In : Antimicrobial Agents and Chemotherapy. Early

    Research output: Contribution to journalArticle

Related by journal

  1. Late presentation with HIV in Africa: phenotypes, risk, and risk stratification in the REALITY trial

    Siika, A., McCabe, L., Bwakura-Dangarembizi, M., Kityo, C., Mallewa, J., Berkley, J., Maitland, K., Griffiths, A., Baleeta, K., Mudzingwa, S., Abach, J., Nathoo, K., Thomason, M. J., Prendergast, A. J., Walker, A. S., Gibb, D. M., Mugyenyi, P., Kityo, C., Musiime, V., Wavamunno, P. & 30 othersNambi, E., Ocitti, P., Ndigendawani, M., Kemigisa, M., Acen, J., Olebo, D., Mpamize, G., Amone, A., Okweny, D., Mbonye, A., Nambaziira, F., Rweyora, A., Kangah, M., Kabaswahili, V., Abach, J., Abongomera, G., Omongin, J., Aciro, I., Philliam, A., Arach, B., Ocung, E., Amone, G., Miles, P., Adong, C., Tumsuiime, C., Kidega, P., Otto, B., Apio, F., Baleeta, K. & REALITY Trial Team, 1 Apr 2018, In : Clinical Infectious Diseases. 66, Issue suppl_2, p. S140-S146

    Research output: Contribution to journalArticle

  2. 2015 epidemic of severe Streptococcus agalactiae sequence type 283 infections in Singapore associated with the consumption of raw freshwater fish: a detailed analysis of clinical, epidemiological, and bacterial sequencing data

    Kalimuddin, S., Chen, S. L., Lim, C. T. K., Koh, T. H., Tan, T. Y., Kam, M., Wong, C. W., Mehershahi, K. S., Chau, M. L., Ng, L. C., Tang, W. Y., Badaruddin, H., Teo, J., Apisarnthanarak, A., Suwantarat, N., Ip, M., Holden, M. T. G., Hsu, L. Y., Barkham, T. & Singapore Group B Streptococcus Consortium, 15 May 2017, In : Clinical Infectious Diseases. 64, suppl_2, p. S145-S152 8 p.

    Research output: Contribution to journalArticle

  3. MRSA transmission dynamics among interconnected acute, intermediate-term, and long-term healthcare facilities in Singapore

    Chow, A., Lim, V. W., Khan, A., Pettigrew, K., Lye, D. C. B., Kanagasabai, K., Phua, K., Krishnan, P., Ang, B., Marimuthu, K., Hon, P-Y., Koh, J., Leong, I., Parkhill, J., Hsu, L-Y. & Holden, M. T. G., 15 May 2017, In : Clinical Infectious Diseases. 64, suppl_2, p. S76-S81 6 p.

    Research output: Contribution to journalArticle

ID: 253439939